ClinicalTrials.gov
public full text
Public Domain
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to evaluate safety of immune tolerance induction (ITI) treatment with turoctocog alfa (a recombinant factor VIII) in patients who have developed neutralising antibodies against factor VIII after exposure to subcutaneous turoctocog alfa pegol during participation in NN7170-4213 (NCT02994407)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients#1164304
- Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A#899543
- A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A#829576
- Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects#1173293
- ATHN 7: Hemophilia Natural History Study#837757
Record · ID 1111957
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive